Language:
Daily summary of financings for therapeutic biotechnology company executives and investors
Thursday, January 15, 2026
Agenus’s $141 Million Venture Financing
MetaVia’s $8 Million Public Offering
Wednesday, January 14, 2026
Caldera’s $112 Million Series A-1
Plus’s $15 Million Public Offering
Beyond’s $5 Million Private Placement
Tuesday, January 13, 2026
Nuclera’s $87 Million Series C
Proxima’s $80 Million Seed Round
Pelthos’s $50 Million Debt Financing
Foghorn’s $50 Million Registered Direct Offering
BriaCell’s $30 Million Public Offering
Converge’s $25 Million Series A
Vivere’s $10 Million Fund Raise
Enspire’s $10 Million Series B1
Monday, January 12, 2026
Mirador’s $250 Million Series B
Precede’s $83 Million Series B
Oricell’s $70 Million Series C
Vibrant’s $61 Million Series B
Trailhead’s $40 Million Fund Raise
Dogwood’s $27 Million Registered Direct Offering
OutSee’s $3 Million Seed Round
Saturday, January 10, 2026
Kinaset’s $103 Million Series B
Friday, January 9, 2026
Orca’s $250 Million Series F
Haemonetics’s $215 Million Acquisition of Vivasure
AirNexis’s $200 Million Series A
Medipost’s $140 Million Fund Raise
Curis’s $81 Million Private Placement
Aptevo’s $60 Million Equity Investment
Clene’s $28 Million Registered Direct Offering
iBio $26 Million Private Placement
Aurora’s $16 Million Seed Round
Thursday, January 8, 2026
Monte Rosa’s $300 Million Public Offering
Alveus’s $160 Million Series A

Century’s $135 Million Private Placement
SonoThera’s $125 Million Series B
Diagonal’s $125 Million Series B
EpiBiologics’s $107 Million Series B
Spruce’s $50 Million Debt Financing
Vizgen’s $48 Million Venture Financing
32 Biosciences’s $40 Million Series A
Engitix’s $25 Million Series A
Enodia’s $24 Million Fund Raise
Genelux’s $20 Million Public Offering…More
Wednesday, January 7, 2026
InduPro’s $950 Million Merger with Lilly
Arrowhead’s $500 Million Debt Financing
Bright Minds’s $175 Million Public Offering
Phathom’s $130 Million Public Offering
Corsera’s $80 Million Series A
Tuesday, January 6, 2026
Amgen’s $840 Million Acquisition of Dark Blue
Praxis’s $575 Million Public Offering
Alumis’s $175 Million Public Offering
Day One’s Acquisition of Mersana
Monday, January 5, 2026
Estrella’s $8 Million Registered Direct Offering
KALA’s $11 Million Debt Financing
Wednesday, December 31, 2025
Hemostemix’s 480K Private Placement
Tuesday, December 30, 2025
Collegium’s $980 Debt Financing
Cybin’s $100 Million Equity Investment
BiomX’s $3 Million Private Placement
Monday, December 29, 2025
Sanofi’s $2 Billion Acquisition of Dynavax
Dermata’s $12 Million Private Placement
Indaptus’s $6 Million Equity Investment
Tuesday, December 23, 2025
Theralase®’s $1 Million Private Placement
Monday, December 22, 2025
Celularity’s $10 Million Debt Financing
Friday, December 19, 2025
Kodiak’s $184 Million Public Offering
Mirum’s $69 Million Private Placement
IN8bio’s $40 Million Private Placement
Cue’s $10 Million Public Offering
BioMarin’s $4.8 Billion Acquisition of Amicus
GeoVax’s $3 Million Public Offering
Thursday, December 18, 2025
Kodiak’s $184 Million Public Offering
Syremis’s $165 Million Series A
Atavistik’S $120 Million Series B
Syneron’s $100 Million Series A and A+
Orum’s $100 Million Equity Investment
CAMP4’D $30 Million Public Offering
Rezubio’s $20 Million Series A
Amphix’s $12 Million Seed Round
Biodexa’s $10 Million Public Offering
Lixte’s $4 Million Registered Direct Offering
Wednesday, December 17, 2025
Ambros’s $125 Million Series A
Kyverna’s $100 Million Public Offering
Alvotech’s $100 Million Debt Financing
Aeovian’s $55 Million Series B
Collabrity Report 2025 – 2026,
All Rights Reserved
Please note that we exclusively feature news related to Biotech Financing.
Securities are offered through Finalis Securities LLC Member FINRA / SIPC. Collabrity is not a registered broker-dealer, and Finalis Securities LLC and Collabrity are separate, unaffiliated entities. Finalis Securities LLC, Office of Supervisory Jurisdiction is located at 450 Lexington Ave, New York, NY 10017, 800-962-0418.
Finalis Privacy Policy | Finalis Business Continuity Plan | FINRA BrokerCheck | Finalis Form Customer Relationship Summary (“Form CRS”)
collabrityreport.com (the “Collabrity Report Website”) is a website operated by Collabrity. This website is for informational purposes only, is not an offer, solicitation, recommendation, or commitment for any transaction or to buy or sell any security or other financial product, and is not intended as investment advice or as a confirmation of any transaction. Products and services on this website may not be available for residents of certain jurisdictions. Please consult with a Finalis Securities’ registered representative regarding the product or service in question for further information. Investments involve risk and are not guaranteed to appreciate. Any market price, indicative value, estimate, view, opinion, data, or other information herein is not warranted as to completeness or accuracy, is subject to change without notice, and Collabrity along with Finalis Securities LLC accepts no liability for its use or to update it or keep it current.
Investing in private placements involves a high degree of risk. These investments may be illiquid, speculative, and subject to substantial restrictions on transferability. Investors may lose all or part of their investment and should only invest capital they can afford to lose. Prospective investors should conduct their own due diligence and consult with their legal, tax, and financial advisors prior to making any investment decision. For your reference, Finalis’ Form CRS describes the services that we provide, how we are compensated, and other important information about Finalis Securities LLC.